Abstract:BACKGROUND: Circulating tumor DNA (ctDNA) is a promising biomarker for non-invasive epidermal growth factor receptor mutations (EGFRm) detection in lung cancer patients, but existing methods have limitations in sensitivity and availability. In this study, we used the ΔCt value (mutant cycle threshold [Ct] value-internal control Ct value) generated during the polymerase chain reaction (PCR) assay to convert super-amplification-refractory mutation system (superARMS) from a qualitative method to a semi-quantitative method named reformed-superARMS (R-superARMS), and evaluated its performance in detecting EGFRm in plasma ctDNA in patients with advanced lung adenocarcinoma.METHODS: A total of 41 pairs of tissues and plasma samples were obtained from lung adenocarcinoma patients who had known EGFRm in tumor tissue and were previously untreated. EGFRm in ctDNA was identified by using superARMS. Through making use of ΔCt value generated during the detection process of superARMS, we indirectly transform this qualitative detection method into a semi-quantitative PCR detection method, named R-superARMS. Both qualitative and quantitative analyses of the data were performed. Kaplan-Meier analysis was performed to estimate the progression-free survival (PFS) and overall survival (OS). Fisher exact test was used for categorical variables.RESULTS: The concordance rate of EGFRm in tumor tissues and matched plasma samples was 68.3% (28/41). At baseline, EGFRm-positive patients were divided into two groups according to the cut-off ΔCt value of EGFRm set at 8.11. A significant difference in the median OS (mOS) between the two groups was observed (EGFRm ΔCt ≤8.11 vs. >8.11: not reached vs. 11.0 months; log-rank P = 0.024). Patients were divided into mutation clearance (MC) group and mutation incomplete clearance (MIC) group according to whether the ΔCt value of EGFRm test turned negative after 1 month of treatment. We found that there was also a significant difference in mOS (not reached vs. 10.4 months; log-rank P = 0.021) between MC group and MIC group. Although there was no significant difference in PFS between the two groups, the two curves were separated and the PFS of MC group tended to be higher than the MIC group (not reached vs. 27.5 months; log-rank P = 0.088). Furthermore, EGFRm-positive patients were divided into two groups according to the cut-off of the changes in ΔCt value of EGFRm after 1 month of treatment, which was set at 4.89. A significant difference in the mOS between the two groups was observed (change value of ΔCt >4.89 vs. ≤4.89: not reached vs. 11.0 months; log-rank P = 0.014).CONCLUSIONS: Detecting EGFRm in ctDNA using R-superARMS can identify patients who are more likely sensitive to targeted therapy, reflect the molecular load of patients, and predict the therapeutic efficacy and clinical outcomes of patients.

Comprehensive Analysis of the Discordance of EGFR Mutation Status Between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung Cancer

Deep Analysis to Inconsistent Results of EGFR Mutation Status in Tumor Tissues and Plasma DNA in Advanced NSCLC.

Correlation of circulating tumor DNA EGFR mutation levels with clinical outcomes in patients with advanced lung adenocarcinoma

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Analysis of Egfr Mutation Status in Tissue and Plasma for Predicting Response to Egfr-Tkis in Advanced Non-Small-Cell Lung Cancer

Circulating Tumor-Dna Profiling to Reveal Heterogeneity of EGFR-TKI Resistance Mechanisms in Lung Adenocarcinoma Patients.

Abstract 2742: Cross-platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Plasma of Patients with Non-Small Cell Lung Carcinoma

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Cross-Platform Comparison Of Four Leading Technologies For Detecting Egfr Mutations In Circulating Tumor Dna From Plasma Of Patients With Non-Small Cell Lung Carcinoma

Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I–III non-small cell lung cancer (NSCLC) patients with baseline tissue EGFR mutations

Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay

Predicting Significance of EGFR Mutation Existing in Tissues and Plasma Concuurrently or Alone to EGFR–tyrosine Kinase Inhibitors (Egfr-Tkis) for Advanced Non-Small Cell Lung Cancer.

Quantification Of Mutant Alleles In Circulating Tumor Dna Can Predict Survival In Lung Cancer

Ctdna Assessment of EGFR Mutation Status in Chinese Patients with Advanced Non-Small Cell Lung Cancer in Real-World Setting

Diagnostic Accuracy of Droplet Digital PCR and Amplification Refractory Mutation System PCR for Detecting EGFR Mutation in Cell-Free DNA of Lung Cancer: A Meta-Analysis

Comparative Analysis of the Representative Value of Somatic Mutation Profiles Derived from Ctdna and Other Updated Lung Tumor Biopsy Alternative in Non-Resectable Non-Small Cell Lung Cancer Patients.

Impact of Plasma EGFR Mutation Fractions on Response to First Generation Tyrosine-Kinase Inhibitor in Treatment of Naïve Non-Small Cell Lung Cancer Patients

Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.

Utility of Circulating Tumor DNA Assay in Identifying Mutations and Guiding Matched Targeted Therapy in Lung Cancers

[Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor]

Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis